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CLINICAL INVESTIGATION
Identification of a low molecular weight inhibitor of osteoblast
mitogenesis in uremic plasma
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tdentlfication of a low molecular weight inhibitor of osteoblast mitoge-
nesis in üremic plasma. A low molecular weight inhibitor of cartilage
sulfation has been detected in the plasma of dialysis patients. Prelimi-
nary studies of this inhibitor have suggested that it may have a role in
decreasing bone mass, possibly by suppressing bone cell proliferation.
Since the in vitro bioassay of crude sulfatjon inhibitor preparations is
relatively nonspecific, we investigated whether. there might also be an
inhibitor of osteoblast mitogenesis in uremic plasma. We fractionated
plasma and plasma ultrafiltrates from dialysis patients by gel filtration
chromatography and looked for inhibition of mitogenesis in cultured
osteoblasts, Material from fractions with a molecular weight range of
750 to 900 inhibited osteoblast mitogenesis. The inhibitory effect,
however, could be overcome with serum or insulin-like growth factor-I,
suggesting that the mechanism of inhibition was not growth factor
dependent. Further characterization of the inhibitor revealed that it was
not a peptide or a polar lipid. We conclude that uremic plasma ëontains
a bone cell mitogenic inhibitor which may have a role in regulating bone
remodeling in adults and bone growth in children.
Although growth factors have received considerable atten-
tion in the regulation of cell proliferation, growth inhibitors may
play an equally important rOle [1—6]. One such inhibitor, with an
estimated molecular weight of 940, is elevated in the plasma of
uremic patients [6]. This low molecular weight inhibitor was
identified by its ability to blunt insulin-like growth factor-I
(IGF-I) stimulated cartilage sulfation, an effect which may be
secondary to reduced DNA and RNA synthesis [6]. It has been
suggested that delayed bone growth in uremic children could be
due, in part, to the suppressive effects of this inhibitor on
growth plate cartilage [61, since this process is controlled
primarily by localized production of IGF-I [7].
Recently, we demonstrated that elevated immunoreactive
plasma IGF-I levels in uremic adults were closely correlated
with increased bone formation [8], a finding consistent with the
anabolic effects of IGF-I in cultured osteoblasts [9, 10]. We also
found, in preliminary studies, that plasma levels of the 940-
dalton uremic inhibitor were significantly elevated in dialysis
patients with reduced bone mass, suggesting that the inhibitor
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may have suppressed bone mineralization [11]. Because ostèo-
blast numbers on bone surfaces were greatly reduced in the
patients with elevated inhibitor levels, we reasoned that the
inhibitor may have decreased bone mass by inhibiting normal
osteoblast proliferation. The purpose of the present study was
to determine whether uremic plasma contains a low molecular
weight inhibitor of osteoblast proliferation. The results indicate
that a circulating inhibitor of osteoblast mitogenesis is present
in uremic plasma and that it acts primarily to suppress basal cell
growth by a mechanism that is independent of IGF-I receptor
stimulation.
Methods
Plasma preparations
For the initial studies a pool was prepared from the plasma of
34 chronic hemodialysis patients. Subsequently, plasma ültrafil-
trates were collected from five uremic patients on hemodialysis.
The ultrafiltrates were obtained by collecting 500 ml of fluid
from each patient while recirculating 500 ml of dialysate on the
venous side of a cuprophane membrane dialyzer (molecular wt
cutoff: 5,000). Each one liter volume was taken to dryness with
a Speed-Vac concentrator (Savant) and reconstituted in 10 ml of
0.1 M ammonium formate, pH 7.0.
Ge/filtration chromatography
A 10 ml aliquot of pooled plasma was fractionated at 4°C
using Sephadex G-25 (superfine) equilibrated in 0.1 M ammo-
nium formate, p11 7.0. Ten milliliter fractions were collected,
taken to dryness and reconstituted in distilled water for assay.
The column was calibrated with the following molecular weight
standards: blue dextran (V0), ['25ljprocalcitonin [1-12] (1650
daltons), ['251]procalcitonin [52-57] (945 daltons), and ['251}thy-
rotropin-releasing hormone (340 daltons). The concentrated
plasma ultrafiltrates were chromatographed in the same man-
ner. Active fractions from chromatography of the ultrafiltrate
preparation were pooled and further characterized.
Osteoblast mitogenic assays
Inhibition of mitogenesis was determined using either pri-
mary cultures of osteoblast-like cells (osteoblasts and osteo-
blast progenitors) from neonatal rat calvaria or U-2 human
osteosarcoma cells (U-2 OS; ATCC, Rockville, Maryland,
USA). Normal osteoblast-like cells were released from calvaria
of 2- or 3-day-old rat pups by collagenase digestion, plated onto
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Fig. 1. Gelfihtration chromatography of pooled uremic plasma. Ten ml
of plasma were fractionated on Sephadex G-25 and fractions assayed
for inhibition of osteoblast mitogenesis using cultures of rat calvaria.
Results are expressed as a percentage of inhibition of cells stimulated
by 5% FBS. Each point represents the mean of 5 separate mitogenic
assays.
96-well plates, and grown in BGJb medium (GIBCO) containing
10% fetal bovine serum (FBS) for 24 hours in a 5% C02-air
atmosphere and then incubated in serum-free BGJb medium for
an additional six to eight hours. The U-2 OS cells were treated
in a similar manner following trypsinization of stock cultures
except that they were grown in McCoys 5a medium (GIBCO)
containing 5% FBS before incubation with serum-free medium.
Following incubation with serum-free medium, mitogenesis
was stimulated by transferring cultures into medium containing
5% FBS or human recombinant IGF-I (50 nglml, Bachem) and
samples to be tested for inhibitory activity were added at this
time. After overnight incubation, [methyl-3H]thymidine (1 jsCil
well; Amersham) was added for a four-hour labelling period.
The cells were then washed, collected onto paper discs by a cell
harvester (Skatron) and the radioactivity quantified in a liquid
scintillation counter.
Proteolytic digestion of inhibitor preparations
Aliquots of inhibitory material were incubated with 1 Unit of
insoluble protease (from Strep. griseus attached to carboxy-
methyl cellulose; Sigma) for 4 and 24 hours in HEPES buffer
containing 2 m calcium at 37°C. The supernatants from the
digestions were assayed for their effect of U-2 OS cell mitogen-
esis. As a control, inhibitory material was incubated with the
enzyme preparation after the protease had been inactivated by
boiling.
Chloroform extraction
Equal volumes of chloroform and mitogenic inhibitory mate-
rial were combined and shaken by hand for two minutes. After
allowing the mixture to stand for 30 minutes at room tempera-
ture, it was centrifuged at 4°C. The aqueous layer was removed
and following reextraction with chloroform, concentrated by
Speed-Vac. The chloroform extracts were pooled and dried
under nitrogen. Residues from the aqueous and chloroform
fractions were reconstituted for the mitogenic assay. Water
controls were extracted and tested in an identical manner.
Results
Chromatography of pooled uremic plasma revealed mitogenic
inhibitory activity in normal osteoblasts in a molecular weight
range of 750 to 900 daltons (Fig. 1). This compares well with the
940 dalton (range of 800 to 1100 daltons) inhibitor of cartilage
sulfation previously identified in uremic plasma [6], using the
same chromatographic procedure. Gel filtration was necessary
to separate this small inhibitor from growth factors that stimu-
late osteoblast proliferation, such as IGF-I [101, and other
growth inhibitors [6, 12]. The inhibitory material was not
cytotoxic since > 90% of the cells excluded trypan blue.
Inhibitory material of the same size was also recovered after gel
filtration of plasma ultrafiltrates (data not shown) and was used
in the subsequent characterizations.
The low molecular weight inhibitor decreased DNA synthesis
in the human U-2 OS osteoblast-like cells (Fig. 2), in both
stimulated and unstimulated cells. The observation that thymi-
dine uptake in FBS-stimulated cells was not suppressible to the
same level as the unstimulated cells suggested that inhibition of
cell growth may not be growth factor specific. To evaluate this
possibility, mitogenic inhibition of normal osteoblasts stimu-
lated by IGF-I (50 ng/ml) was compared to inhibition of unstim-
ulated cells (Fig. 3). Inhibition of IGF-I-stimulated mitogenesis
(70%) was similar to inhibition in the unstirnulated controls
(72%). That is, IGF-I stimulated osteoblast mitogenesis by
about 1.8-fold, regardless of whether the inhibitory material
was present or not.
Because previous studies demonstrated that some low mo-
lecular weight uremic inhibitors of DNA synthesis are peptides
[5], we evaluated this possibility by testing our inhibitory
material following protease digestion. As shown in Figure 4,
prolonged incubation with a nonspecific protease did not alter
the inhibitory activity in the mitogenic assay. Since the inhibitor
was not a peptide, we attempted to extract the material with
chloroform to assess the possibility that the active substance
might be a polar lipid (Fig. 5). Uremic plasma has been shown
to contain polar lipids that inhibit erythropoiesis [13]. In the
mitogenic assay no inhibitory activity was extracted into chlo-
roform and all of the inhibition was recovered in the aqueous
layer.
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Fig. 2. Inhibition of mitogenesis in U-2 OS cells. The amount of
inhibitor (INHIB) tested was 3% of the total volume of culture medium
(100 sl). Values are the mean SD of 3 experiments. < 0.05 vs.
control; ** < 0.05 vs. FBS-stimulated.
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Fig. 3. Inhibition of mitogenesis in IGF-stimulated rat osteoblasts.
lOP-I, 50 ng/ml, was used to stimulated mitogenesis. The amount of
inhibitor (Inhib) tested was 3% of the total volume of culture medium
(100 tl). Values are the mean SE of 6 wells. *P C 0.05 vs. control; **
<0.05 vs. lOP-stimulated.
Control Protease Control Protease
4hr. 24hr.
Fig. 4. Lack of effect of protease digestion on inhibitory activity in U-2
OS cells. The inhibitor preparation was treated with protease for 4 or 24
hours and then tested at a concentration of 3% (vol/vol). Values are the
mean su of 2 or 3 experiments.
Discussion
We have shown that a low molecular weight inhibitor of
osteoblast mitogenesis exists in the circulation of uremic pa-
tients undergoing hemodialysis. The mitogenic inhibitor, which
is not a peptide, is similar in size to the 940-dalton uremic
inhibitor of cartilage sulfation and DNA synthesis identified by
Phillips et al [6]. Although their inhibitor was originally reported
to be partially inactivated by protease, a more recent charac-
terization of this material by these authors suggests that it is not
a peptide [14]. While the similar characteristics of these two
inhibitors of DNA synthesis suggest that they may be the same
-I I t k
Control Inhib Organic Aqueous
Fig. 5. Effect of chloroform extraction on inhibitor activity in U-2 OS
cells. Inhib., untreated inhibitory material; Organic, chloroform phase;
and Aqueous, aqueous phase. Control cultures contained 5% PBS and
the inhibitor concentration tested was 3% (vol/vol) for all conditions.
Values are for one experiment with the mean sD of 8 wells. C 0.05
vs. control.
molecule, the final comparison must await complete purification
of both inhibitors.
Although the mechanism of inhibition was not fully exam-
ined, our finding that the inhibitor decreased basal (unstimulat-
ed) proliferation suggested that it may interfere with the auto-
crime regulation of cell growth. Since several osteoblast-derived
growth factors, including IGF-I, stimulate osteoblast mitogen-
esis [15—17], inhibition of either their production or their recep-
tor binding could decrease basal growth rates. When we tested
serum-stimulated as well as IGF-I-stimulated cells, we found
that cells treated with the inhibitory material were stimulated by
the same amount as cells not exposed to the inhibitor. Thus, the
inhibitor may decrease DNA synthesis by an effect which is not
dependent on growth factor-receptor stimulation. Whether it
decreases basal growth rates by decreasing production of
osteoblast-derived growth factors remains to be determined.
Our recent preliminary study in uremic patients showing that
elevated plasma levels of the 940 dalton inhibitor were associ-
ated with histological reductions in osteoblast number [11],
together with the current in vitro data, suggest that inhibition of
osteoblast proliferation may be an important cause of reduced
bone mass in certain uremic patients with low turnover osteo-
dystrophy [18]. The observation that IGF-I mitigates the mito-
genic inhibitory effect in vitro may explain why some uremic
patients with presumed elevations of the plasma inhibitor have
normal or enhanced bone cell function when circulating levels
of IGF-I and/or PTH, a stimulator of osteoblast-derived IGF-I
[19], are also elevated [8]. In addition to its possible effects on
osteoblast function in adults, the inhibitor may also have a role
in causing delayed bone growth and short stature in uremic
children. This could occur as a consequence of decreased
osteoblast growth following the formation and proliferation of
growth plate cartilage.
While the identity of the mitogenic inhibitor is unknown, it
does not appear to be a protein or a protein fragment of known
growth inhibitors [1—5]. In addition, failure to extract the
inhibitory material in chloroform suggests that it is not the
lipid-like inhibitor of erythropoiesis identified in uremic serum
[13]. Whether the mitogenic inhibitor is related to the circulat-
a)
0.0
C
3
2
0
a)
ClCai
'DxC
>nr3
28
21
14
7
0
j
0
L1i
Control IGF-l Inhib OF-I
+
inhib
a)S
Ca
0.
a)C0
E
-c
0
C0
.0
.0C
100
90
80
70
60
50
40
30
20
10
0
/
Andress et al: Inhibitor of osteoblast mitogenesis 945
ing low molecular weight acidic polyol inhibitor of nerve cell
function [201 or to pentosidine [211, has not been ruled out.
In conclusion, we have isolated a circulating low molecular
weight inhibitor of osteoblast mitogenesis in uremic patients.
The inhibitor, which is not a peptide, acts to decrease basal cell
proliferation but not DNA synthesis stimulated by IGF-I or
serum. We suggest that this uremic inhibitor may have a
permissive role in suppressing bone remodeling in adults and
bone growth in children.
Acknowledgments
This work was supported by the Department of Veterans Affairs. Dr.
Andress is a V.A. Research Associate.
Reprint requests to Dennis L. Andress, M.D., Veterans Affairs
Medical Center, Dialysis Unit (lilA), Seattle, Washington 98108,
USA.
References
1. MASHIMA K, KIMuit T, HUANG W, YANO K, ASHIDA Y, YAMA-
GATA Y, MIYAZAKI K, YAMASHITA J, Hoiuo T: Multiple forms of
growth inhibitors secreted from cultured rat liver cells: Purification
and characterization. J Biochem 103:1020—1026, 1988
2. BLAT C, BOHLEN P, VILLAUDY J, CHATELAIN G, GOLDa A,
HAREL L: Isolation and amino-terminal sequence of a novel cellular
growth inhibitor (inhibitory diffusible factor 45) secreted by 3T3
fibroblasts. J Biol Chem 264:6021—6024, 1989
3. ERVIN PR JR, KAMIN5KI MS, CODY RL, WICHA MS: Production of
mammastatin, a tissue-specific growth inhibitor, by normal human
mammary cells. Science 244:1585—1587, 1989
4. LEBOEUF RD, BURN JN, BOST KL, BLAL0CK JE: Isolation,
purification and partial characterization of suppressin, a novel
inhibitor of cell proliferation. J Biol Chem 265:158—165, 1990
5. GUTMAN RA, HUANG AT: Inhibitor of marrow thymidine incorpo-
ration from sera of patients with uremia. Kidney mt 18:715—724,
1980
6. PHILLIPS LS, Fusco AC, UNTERMAN TG, DEL Gico F: So-
matomedin inhibitor in uremia: J Clin Endocrinol Metab 59:764—
772, 1984
7. Nnssor A, ISGAARD J, LINDAHL A, DAHL5TROM A, SKOTTNER A,
IsAKssoN OGP: Regulation by growth hormone of number of
chondrocytes containing IGF-I in rat growth plate. Science 233:
571—574, 1986
8. ANDRESS DL, PANDIAN MR, ENDRES DB, Ko JB: Plasma
insulin-like growth factors and bone formation in uremic hyperpara-
thyroidism. Kidney mt 36:471—477, 1989
9. HOWARD GA, SPENCER EM: Somatomedins A and C directly
stimulate bone cell proliferation in vitro, in Endocrine Control of
Bone and Calcium Metabolism (vol 8A), edited by COHN DV,
FUJITA T, POTTS JT JR, TALMAGE RV, Amsterdam, Excerpta
Medica, 1984, pp. 86—89
10. HOCK JM, CENTRELLA M, CANALIS E: Insulin-like growth factor I
has independent effects on bone matrix formation and cell replica-
tion. Endocrinology 122:254—260, 1988
11. ANDRESS DL, PHILLIPS LS, SI-IERRARD Di: Elevated plasma so-
matomedin inhibitor in osteopenic diabetic dialysis patients. (ab-
stract) Kidney mt 3 1:341, 1987
12. PHILLIPS LS, BELOSKY DC, YOUNG HS, REICHARD LA: Nutrition
and somatomedin. VI. Somatomedin activity and somatomedin
inhibitory activity in serum from normal and diabetic rats. Endo-
crinology 104:1519—1524, 1979
13. WALLNER SF, VAUTRIN RM: The anemia of chronic renal failure:
Studies of the effects of organic solvent extraction of serum. J Lab
Clin Med 92:363—369, 1978
14. PHILLIPS LS, GOLDSTEIN S, KLEIN JD, SULINSKI CM, EL-KEBBI
IM, ZIEMER DC, POLLET Ri, STULTS J: Uremic serum growth
inhibitor. (abstract) Clin Res 38:33A, 1990
15. HELDIN C-H, JoHNssoN A, WENNERGREN S, WERNSTEDT C,
BETCHOLTZ C, WESTERMARK B: A human osteosarcoma cell line
secretes a growth factor structurally related to a homodimer of
PDGF A-chains. Nature 319:511—514, 1986
16. ROBEY P, YOUNG MF, FLANDERS KC, ROCHE NS, KONDAIAH P,
REDDI AH, TERMINE JD, Spoiu' MB, ROBERTS AB: Osteoblasts
synthesize and respond to transforming growth factory-type beta
(TGF/3) in vitro. J Cell Biol 105:457—462, 1987
17. CANALIS E, MCCARTHY T, CENTRELLA M: Isolation and charac-
terization of insulin-like growth factor I (somatomedin C) from
cultures of fetal rat calvariae. Endocrinology 122:22—27, 1988
18. ANDRESS DL, HERCZ G, KoP JB, ENDRES DB, Noluils KC,
COBURN JW, SHERRARD Di: Bone histomorphometry of renal
osteodystrophy in diabetic patients. J Bone Miner Res 2:525—531,
1987
19. MCCARTHY IL, CENTRELLA M, CANALIS E: Parathyroid hormone
enhances the transcript and polypeptide levels of insulin-like
growth factor I in osteoblast-enriched cultures form fetal rat bone.
Endocrinology 124:1247—1253, 1989
20. MAN NK, CUEILLE G, ZINGRAFF J, DRUEKE T, JUNGERS P,
SAU55E A, BOUDET J, FUNCK-BRENTANO JL: Evaluation of plasma
neurotoxin concentration in uremic polyneuropathic patients. Proc
Eur Dial Transpl Assoc 5:164—170, 1978
21. SELL DR, MONNIER VM: End-stage renal disease and diabetes
catalyze the formation of a pentose-derived crosslink from aging
human collagen. J Clin Invest 85:380—384, 1990
